# GSE168204 evaluation: source and provenance review

**Recorded 2 October 2026, after Claude Code run 1.** File hashes below identify the files examined now. This note does not claim that a copy made today was frozen before the model answered.

## Reference provenance

The three reference artifacts had been saved before the candidate run. Their Library creation records are 1 October 2026 at 14:26:58–14:27:02 UTC (15:26:58–15:27:02 BST); the recorded modification times are the same. The first candidate answer completed at about 23:34 BST on 1 October. The reference artifacts were kept outside the candidate's initial three-file workspace. These records support the chronology, but a pre-run Git commit or timestamped, signed bundle of the exact Windows-side files has **not** been supplied. The following SHA-256 values are for the files reviewed for this note; do not describe the hashes as if they were recorded before the run.

| Reference file | SHA-256 checked on 2 October |
| --- | --- |
| `evaluation_handoff.md` | `59caf05a3c348c57e9adc7df06115183e2d779edf580569f351b351c7cb7a4bf` |
| `mapping_audit.md` | `9110ac73cb41fbc625c9a63b30fe175fa5d0f49627b0d35f0fa9edf9726a6c60` |
| `sample_metadata_curated.csv` | `fa885075cf6d4e91b53913b92a691f225c3f71b2b393bf0fc568efc38ab2c4ec` |

In this public copy, the three reference files are in `reference/`, and this post-run note and `claude-session1-scorecard.md` are in `audit/`. The status statements in the reference files describe the pre-run state and have not been rewritten after scoring.

## What the public source establishes

- The [GEO series GSE168204](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE168204) lists 27 samples and describes frozen or formalin-fixed tumour specimens. It says the study investigated biopsy sites at the same biopsy time point. The titles include two `MGHIPIPD1001_070215_*` records and three `MGHIPIPD1001_070715_*` records.
- The corresponding [published study](https://hub.hku.hk/bitstream/10722/318956/1/content.pdf), *Nature Communications* 12:6023 (2021), describes 27 newly generated MGH pre/on treatment specimens. Its reported 50-sample MGH validation cohort **combines** this accession with previously published MGH data, so those 50 should not be treated as 50 GSE168204 samples. The methods say duplicated specimens at the same timepoint were excluded from the authors' analysis, but the text does not map that exclusion to each raw GEO record. The paper's newly generated MGH sequencing paragraph says RNA came from fresh frozen tumours, while the GEO series describes frozen or formalin-fixed material and some sample titles contain `FFPE`; this processing description also needs reconciliation before making a per-sample assertion.
- [GSM5133931](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM5133931) is recorded as PRE, day −433, patient 27. The supplied GEO-derived sample metadata records [GSM5133918](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM5133918) as PRE, day +21, patient 200. The paper and accessible GEO summaries do not explain the precise origin of day zero or reconcile the +21 PRE label. The paper's response definition is RECIST CR/PR or SD with PFS >180 days for R, and PD or SD with PFS <180 days for NR.
- The publisher's **Supplementary Data 1**, `41467_2021_26299_MOESM3_ESM.xlsx` (SHA-256 `322c6287316fcb52a580a588266a53c9b0fd7bec0b67e80a6476a6ac4e58212e`), was examined on 2 October. Sheet `1d` summarises the combined MGH cohort by patient ID, treatment, PRE/ON label, best overall response, PFS, OS and response group. It confirms patient 200 received atezolizumab and patient IPIPD1001 received ipilimumab plus nivolumab; IPIPD1001 has one PRE and six ON rows there. The sheet has no GSM accession, specimen/site identifier, collection date or day-zero definition. Its 53 populated data rows should not be assumed to map one-to-one to the 27 GEO samples.

**Still unresolved after checking Supplementary Data 1:** which same-day GSMs are distinct sites/specimens versus technical replicates or multiple libraries, and whether the unusual PRE day values satisfy a strictly pretreatment baseline under the original clinical timeline. A sample-level specimen key and a treatment-start/date definition would be needed to settle these. Until then, report the questions as unknown and retain the eight-person core as a proposed sensitivity subset, not a source-certified baseline cohort. Do not revise the prespecified score in response to new source material without a labelled post-run correction.

## Transcript for public release

The private original `claude-code-full-execution-transcript1.txt` has SHA-256 `45d9b3519167c09c8a817ddbae0d3799e9242a40f1d76da4db9e688ccc7d0297`. A separate `claude-code-full-execution-transcript1-public.txt` replaces the local username, project paths, Claude temporary session directory and Python paths with bracketed placeholders. Its SHA-256 is `dc2a2c58d76cc3058416b81fe73ebd985737ab3ab6efc176c8b2a70f5cc03e8d`. The prompt, order of actions, failures, first answer and later repair remain visible. The original is retained privately; the public copy has an appended redaction note. A scan of this attached public copy found no username, email address or absolute local path. It does mention Dropbox once without exposing a folder path.

## Publication decision

The evaluation result (first answer 12/16) and its execution trace are ready to report. For the case study, state the reference chronology and its provenance limit precisely, use the redacted public transcript, and keep specimen/timing assertions within what the source establishes. Supplementary Data 1 has been checked and does not resolve the remaining questions. A stronger assertion about the strict baseline cohort or same-day specimen identity needs a GSM-level specimen key and the clinical timing definition.
